Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients′ Response to Biological Therapy and the Need for Colectomy

Author:

Di Ruscio Mirko,Variola Angela,Vernia Filippo,Lunardi Gianluigi,Castelli Paola,Bocus Paolo,Geccherle Andrea

Abstract

<b><i>Background:</i></b> The main goal in the treatment of ulcerative colitis (UC) is to achieve mucosal healing. Despite being unvalidated, the most widely used scoring system is the Mayo endoscopic subscore (MES). However, the recently established and validated Ulcerative Colitis Endoscopic Index of Severity (UCEIS) represents an interesting alternative method in assessing endoscopic disease activity. <b><i>Objective:</i></b> Due to a lack of reliable prognostic factors, the aim of this study was to investigate the diagnostic accuracy of the UCEIS and the MES, in predicting response to biological therapy and the need for colectomy. <b><i>Methods:</i></b> We conducted a retrospective, uncontrolled, single-center study on UC patients with endoscopically active disease even with concomitant conventional and/or biological therapy, who had already started or had been changed a biological treatment. <b><i>Results:</i></b> Sixty-one UC patients were enrolled. At baseline, 71% were naive to biological therapies and 41% had an extensive colitis. At control time (median time of 11.5 months), MES and UCEIS scores significantly decreased from those at baseline (from 2.6 to 1.8 and 5 to 3.2, respectively, <i>p</i> &#x3c; 0.001). UCEIS, but not MES, was found to be significantly associated with unresponsiveness to therapy (<i>p</i> = 0.040). Moreover, when UCEIS was ≥7, all patients underwent colectomy after a median time of 5 months (<i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> UCEIS may be superior to MES because of its accuracy and predictive role. Therefore, UCEIS should be considered for use in daily clinical practice.

Publisher

S. Karger AG

Subject

Gastroenterology

Reference36 articles.

1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.

2. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–86.

3. Marchal Bressenot A. Which evidence for a treat to target strategy in ulcerative colitis?. Best Pract Res Clin Gastroenterol. 2018;32–33:3–8.

4. Darr U, Khan N. Treat to target in inflammatory bowel disease: an updated review of literature. Curr Treat Options Gastroenterol. 2017;15(1):116–25.

5. Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17(9):1673–79.e1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3